DK2408807T3 - Fremgangsmåde til terapeutisk anvendelse - Google Patents
Fremgangsmåde til terapeutisk anvendelse Download PDFInfo
- Publication number
- DK2408807T3 DK2408807T3 DK10710017.4T DK10710017T DK2408807T3 DK 2408807 T3 DK2408807 T3 DK 2408807T3 DK 10710017 T DK10710017 T DK 10710017T DK 2408807 T3 DK2408807 T3 DK 2408807T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic use
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16116509P | 2009-03-18 | 2009-03-18 | |
US25602809P | 2009-10-29 | 2009-10-29 | |
PCT/EP2010/053519 WO2010106127A2 (en) | 2009-03-18 | 2010-03-18 | Method for therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2408807T3 true DK2408807T3 (da) | 2021-08-09 |
Family
ID=42376556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10710017.4T DK2408807T3 (da) | 2009-03-18 | 2010-03-18 | Fremgangsmåde til terapeutisk anvendelse |
Country Status (17)
Country | Link |
---|---|
US (1) | US20100285108A1 (da) |
EP (2) | EP2408807B1 (da) |
JP (2) | JP2012520852A (da) |
KR (1) | KR20120004994A (da) |
CN (1) | CN102428101B (da) |
AU (1) | AU2010224824B2 (da) |
CA (1) | CA2755683A1 (da) |
DK (1) | DK2408807T3 (da) |
ES (1) | ES2885398T3 (da) |
HU (1) | HUE055739T2 (da) |
IL (1) | IL214919A (da) |
MX (1) | MX2011009654A (da) |
PT (1) | PT2408807T (da) |
RU (1) | RU2579659C2 (da) |
SG (1) | SG174871A1 (da) |
SI (1) | SI2408807T1 (da) |
WO (1) | WO2010106127A2 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
CA3120504A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
JP6371526B2 (ja) | 2010-10-07 | 2018-08-08 | エーシー イミューン エス.エー. | タウを認識するリン酸化部位特異的抗体 |
KR102129220B1 (ko) * | 2011-09-23 | 2020-07-02 | 에이씨 이뮨 에스.에이. | 백신 요법 |
KR101981351B1 (ko) * | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
JP6293731B2 (ja) | 2012-04-05 | 2018-03-14 | エーシー イミューン エス.エー. | ヒト化タウ抗体 |
CN104428411B (zh) * | 2012-05-08 | 2018-11-23 | 健康科学西部大学 | 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台 |
KR102233349B1 (ko) | 2013-03-15 | 2021-03-31 | 에이씨 이뮨 에스.에이. | 항-타우(tau) 항체 및 사용 방법 |
EP3166688B1 (en) | 2014-07-08 | 2024-08-21 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
ES2852001T3 (es) | 2015-01-23 | 2021-09-10 | Helix Biopharma Corp | Conjugados de anticuerpo-ureasa para propósitos terapéuticos |
US10988528B2 (en) | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
EP3700556A2 (en) * | 2017-10-25 | 2020-09-02 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
US11684576B2 (en) | 2019-02-08 | 2023-06-27 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
JOP20210284A1 (ar) | 2019-04-24 | 2023-01-30 | Janssen Pharmaceuticals Inc | الإعطاء غير المتجانس للقاحات تاو |
WO2024156908A1 (en) | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Liposomal construct |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
WO1994013795A1 (en) * | 1992-12-14 | 1994-06-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
WO1997034145A1 (fr) * | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
JP2004503747A (ja) * | 2000-07-11 | 2004-02-05 | モレキュラー ジェリアトリクス コーポレイション | 結合物質の同定するための試薬と方法 |
KR20050101537A (ko) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
EP1494000A1 (en) * | 2003-07-02 | 2005-01-05 | Sicpa Holding S.A. | Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material |
US20050261475A1 (en) * | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
JP4934433B2 (ja) * | 2004-02-20 | 2012-05-16 | エーシー イミューン ソシエテ アノニム | 超分子コンストラクトを含む方法および組成物 |
KR101236611B1 (ko) * | 2005-12-12 | 2013-03-04 | 에이씨 이뮨 에스.에이. | 치료 백신 |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція |
-
2010
- 2010-03-18 CN CN201080021554.XA patent/CN102428101B/zh active Active
- 2010-03-18 MX MX2011009654A patent/MX2011009654A/es active IP Right Grant
- 2010-03-18 SG SG2011067097A patent/SG174871A1/en unknown
- 2010-03-18 EP EP10710017.4A patent/EP2408807B1/en active Active
- 2010-03-18 CA CA2755683A patent/CA2755683A1/en not_active Abandoned
- 2010-03-18 PT PT107100174T patent/PT2408807T/pt unknown
- 2010-03-18 HU HUE10710017A patent/HUE055739T2/hu unknown
- 2010-03-18 ES ES10710017T patent/ES2885398T3/es active Active
- 2010-03-18 JP JP2012500251A patent/JP2012520852A/ja not_active Withdrawn
- 2010-03-18 AU AU2010224824A patent/AU2010224824B2/en active Active
- 2010-03-18 DK DK10710017.4T patent/DK2408807T3/da active
- 2010-03-18 RU RU2011141889/10A patent/RU2579659C2/ru active
- 2010-03-18 SI SI201032083T patent/SI2408807T1/sl unknown
- 2010-03-18 US US12/661,628 patent/US20100285108A1/en not_active Abandoned
- 2010-03-18 EP EP21180474.5A patent/EP3978517A1/en active Pending
- 2010-03-18 KR KR1020117024550A patent/KR20120004994A/ko not_active Application Discontinuation
- 2010-03-18 WO PCT/EP2010/053519 patent/WO2010106127A2/en active Application Filing
-
2011
- 2011-09-01 IL IL214919A patent/IL214919A/en active IP Right Grant
-
2015
- 2015-07-06 JP JP2015134900A patent/JP2015221809A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2011009654A (es) | 2011-10-12 |
HUE055739T2 (hu) | 2021-12-28 |
AU2010224824A2 (en) | 2011-09-22 |
JP2012520852A (ja) | 2012-09-10 |
ES2885398T3 (es) | 2021-12-13 |
EP3978517A1 (en) | 2022-04-06 |
CN102428101B (zh) | 2016-03-02 |
AU2010224824A1 (en) | 2011-09-22 |
RU2011141889A (ru) | 2013-04-27 |
CA2755683A1 (en) | 2010-09-23 |
JP2015221809A (ja) | 2015-12-10 |
IL214919A (en) | 2016-10-31 |
WO2010106127A3 (en) | 2011-03-31 |
SI2408807T1 (sl) | 2021-11-30 |
WO2010106127A2 (en) | 2010-09-23 |
AU2010224824B2 (en) | 2014-02-20 |
RU2579659C2 (ru) | 2016-04-10 |
IL214919A0 (en) | 2011-11-30 |
EP2408807B1 (en) | 2021-07-21 |
PT2408807T (pt) | 2021-09-03 |
CN102428101A (zh) | 2012-04-25 |
KR20120004994A (ko) | 2012-01-13 |
EP2408807A2 (en) | 2012-01-25 |
US20100285108A1 (en) | 2010-11-11 |
SG174871A1 (en) | 2011-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2017047I1 (el) | Συνδυαστικη θεραπεια για χαπ | |
DK2408807T3 (da) | Fremgangsmåde til terapeutisk anvendelse | |
BR112012004707A2 (pt) | método | |
BR112012000624A2 (pt) | método | |
FI20090389A0 (fi) | Menetelmä | |
BR112012015988A2 (pt) | método | |
ATE526024T1 (de) | Fluvoxamin vermeidende pirfenidontheraphy | |
BRPI1012526A2 (pt) | método | |
BRPI1010705A2 (pt) | método | |
BRPI0917684A2 (pt) | método terapêutico homeopático | |
DK2310613T3 (da) | Forbedret brudled til stigrør | |
DK2513288T3 (da) | Indretning til kontinuerlig dyrkning | |
BRPI1012532A2 (pt) | método | |
BR112013009024A2 (pt) | método | |
BR112012023891A2 (pt) | método | |
BRPI1009350A2 (pt) | método | |
ITPD20090053U1 (it) | Paradordi per banchine | |
BRPI1013903A2 (pt) | tratamentos terapêuticos utilizando centaquina | |
BR112013015580A2 (pt) | método de radioestabilização | |
BR112012033000A2 (pt) | método | |
ES1070798Y (es) | Ataud | |
DK2404510T3 (da) | Indretning til temperering | |
TH105556B (th) | สารประกอบ และ วิธีการใหม่สำหรับการบำบัด | |
IT1396653B1 (it) | Apparato | |
IT1396965B1 (it) | Dispositivo terapeutico |